DelveInsight’s 'Non-Cystic Fibrosis Bronchiectasis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline non-cystic fibrosis bronchiectasis therapies in various stages of ...

Electromed Inc (ELMD) reports a robust 19% increase in net revenue, driven by strategic growth in home care and hospital ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity ...

At the recent American College of Allergy, Asthma & Immunology (ACAAI) annual meeting, experts discussed the evolving concept ...

Bronchiectasis is a chronic lung disease that develops when the bronchi (airways) are damaged and permanently widen. It is a progressive condition that causes scarring and thickening of the bronchial ...

He said: “People with lung conditions like asthma, chronic obstructive pulmonary disease (COPD) or bronchiectasis are also ...

Reports Q3 revenue $3.0M vs. $1.2M last year. As of September 30, Armata held approximately $17.1M of unrestricted cash and cash equivalents ...

Verona Pharma (Nasdaq: VRNA) is already recording millions of dollars in revenue after launching its lead drug in August ...

Electromed ( (ELMD) ) has released its Q1 earnings. Here is a breakdown of the information Electromed presented to its investors. Electromed, ...

COLUMBIA, Mo. (KY3) - A new form of diagnostic imaging is changing how doctors see and treat lung conditions like cystic ...

Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.

Insmed also said its NDA submission for Brensocatib in Bronchiectasis is on track for the fourth quarter and is expected to ...